Mario E Napoles, MD

Cardiology and Imaging Specialist. Assistant Prof. Specialist in Cardiac and Vascular tomography applications. Head of the Department of Imaging. @FiRSTSCCT

[Mario E Napoles, MD @MarioENapoles]

https://t.co/IbbYzHsMCj

[Dr. Filippo Cademartiri @FCademartiri]

When any cardiovascular risk score will provide confidence intervals for the population, we will make a small step forward from the current foggy version of risk assessment that it is offered. However, only having an individualized risk score can really change the prognosis of the individual patient and that type score does not exist unless driven by coronary imaging.

If you want to properly assess cardiovascular risk, the best option we have currently is Cardiac CT. From there you can start a preventative approach for the individual patient.

[Dr. Filippo Cademartiri @FCademartiri]

🧠🔬 Dual-Source Photon Counting CT for Spectral Evaluation of Coronary Atherosclerosis 💥🫀

The new frontier in cardiovascular imaging is already here — and it speaks the language of photons 📡 and spectral tissue characterization 🌈.
Photon Counting CT (PCCT) with a dual-source system brings together two groundbreaking technologies.

This combination enables advanced spectral assessment of coronary plaques in a single acquisition, with enhanced spatial resolution and native spectral sensitivity — no artificial post-processing needed.

🎯 Why is it so powerful for coronary atherosclerosis?

🔹 Native multi-energy acquisition
PCDs discriminate the energy of each individual photon 💎, allowing true voxel-based multi-energy imaging, without interpolation.

🔹 Tissue composition analysis of plaques
Spectral data allows differentiation between:

🟤 Lipid-rich plaque
⚪ Fibrous plaque
⚫ Calcified plaque

🔹 Early identification of vulnerable plaques
Low attenuation plaque (<30 HU), “napkin-ring” signs, and other high-risk features are better characterized thanks to detailed spectral information 📊.

🔹 Calcium artifact reduction
With virtual monoenergetic images (VMI), you can “navigate” through energy levels (e.g. 40–190 keV) ⚙️ to optimize contrast and reduce blooming artifacts 🧊.

🔹 Precise iodine quantification
Volumetric quantification of intra-plaque iodine, intraluminal enhancement, or perivascular uptake opens new paths for evaluating inflammation, neoangiogenesis, and capillary permeability 🔥.

🔹 UHR resolution
Thanks to sub-millimetric pixel sizes (0.1 mm) and no electronic cross-talk, even microcalcifications and thin fibrous caps can be detected with confidence 🧩.

🔹 One scan, multiple insights
A single coronary scan yields:

Standard morphological images
Spectral maps (iodine, VMI, Z-effective, electron density)
Advanced reconstructions (plaque maps, subtraction images, etc.)

🚀 PCCT + Dual Source = Coronary CT 3.0

A technology that enhances diagnosis, anticipates clinical events, and makes the invisible visible.
Key benefits in:
✅ Prevention
✅ Risk stratification
✅ Monitoring anti-atherosclerotic therapies
✅ Clinical and translational research

#PhotonCountingCT #CardiacImaging #Innovation #SpectralImaging #CardiacCT #PlaqueVulnerability #AIinCardiology #PlaqueImaging #InnovationInImaging #NAEOTOMAlpha #SiemensHealthineers

[Patricia Rodriguez-Lozano MD, MS 🇵🇪🫀 @PRodriguezMD]

Thrilled to be speaking at #ACCLATAM #ACCLATAM2025 in #MexicoCity 🇲🇽!
I’ll present Microvascular Disease in Women during the session Imaging in Ischemia & Viability in the Current Era — Friday, Sept 19, 3:50–4:40 pm, Salon Chapultepec B @ACCinTouch @ChrisKramerMD @onco_cardiology @CardioUva @UVACardsFellows @uvahealthnews

[European Society of Cardiology @escardio]

In a few weeks, cardiology professionals will gather at #ESCCongress 2025 with #WCCardio for an unforgettable experience.

Enjoy networking opportunities, celebrations, entertainment, CV health checks, & so much more.

See what’s waiting in Madrid & register by 31 July to save https://t.co/8E8wQ8Ieb1

#ESC75Years #LETSRISE2025

[Diego Segura-Rodríguez @SeguraCardio]

Late gadolinium enhancement on cardiac MRI❤️‍🔥

Has #LGE changed how YOU risk-stratify or treat? Drop your pearls + cases below! 🗣️💡

Follow me for more insights 💫
#WhyCMR #SCD

[Dr. Filippo Cademartiri @FCademartiri]

🎯 FISI 2025 – Frankfurt Interdisciplinary Symposium on Innovative Diagnostics and Therapy

🗓 17–18 October 2025 | 📍 Universitätsmedizin Frankfurt | 🌐 Hybrid (On-site + Online)

💥 “State of the Art CT: Innovation trifft Diagnostik”
🫀 Dr. Filippo Cademartiri
💡 “Photon-Counting CCTA: A New Dimension?”

📅 Saturday, 18 October – 09:40
📍 Session 5: Kardiovaskuläre Diagnostik

I will join the program of this great event with a talk about advanced cardiovascular imaging using Photon Counting CT that is redefining coronary imaging — from plaque characterization to precision prevention.
📸 IVUS-like resolution, multi-contrast capabilities, and a paradigm shift in cardiac diagnostics.

🚀 “This is not just a better CT. It’s a new modality.”

🔍 Highlights of FISI 2025

✅ Cutting-edge CT technologies
✅ Cardiac, neuro, thoracic, MSK, abdominal sessions
✅ Live cases & industry talks (Siemens, GE, Canon, Philips)
✅ CME-accredited | Hybrid access | Networking opportunities

💬 Learn more & register: https://t.co/9vwoOedBKO
📌 Early registration until 30 August
🎓 Free for students
🫀 Let’s bring the future of cardiac imaging into clinical reality.

🧠 #PhotonCountingCT #CardiacCT #FISI2025 #CCTA #RadiologyInnovation #DrCademartiri #FrankfurtCT #HybridCongress

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

Cannot wait for #ESCCongress 2025 #WCCardio. Madrid and the meeting will be fantastic fun!

[Pablo Corral MD @drpablocorral]

💉Targeting Triglycerides: The Future is Here

👉From ApoCIII to ANGPTL3 and FGF-21 analogues, new siRNA and ASO therapies are transforming the landscape of hypertriglyceridemia management.

📉 TG reductions reaching up to 80%!

👉Mild to severe HTG, monogenic or multifactorial — new options are emerging across the board.

1️⃣ Mild to moderate HTG (first slide):
👉siRNA vs ANGPTL3 vs ApoCIII:
In mild-to-moderate HTG, agents like Plozasiran and Zodasiran are showing up to 63% TG reduction in phase 2b trials.
👉Weekly vs quarterly dosing, different targets, different strategies.
Stay tuned as these agents move toward phase 3.

2️⃣ Severe HTG (FCS/MCS - second slide):
👉Managing sHTG and FCS is no longer science fiction.
Volanesorsen (ASO) leads with up to 88% TG lowering, while siRNA agents like 👉Plozasiran show promise with 80% reduction in FCS.
New frontiers, real hope for patients at highest pancreatitis risk.

@society_eas
@TriglycerideF

[Jae K. Oh @JaeKOh2]

Amazing @CASivaram1 electrical and Doppler correlation!
Great to learn something I did not know before.

[Mario E Napoles, MD @MarioENapoles]

https://t.co/pynjVyK5Ns

[Patricia Rodriguez-Lozano MD, MS 🇵🇪🫀 @PRodriguezMD]

So proud of my team for presenting our work on contrast-enhanced CT in aortic stenosis: Assessment of Fibrocalcific Remodeling and Correlation with Echocardiographic Parameters. Exciting science and even better teamwork! 👏🫀 #SCCT2025 #yesCCT @Heart_SCCT @UVA @CardioUva @UVACardsFellows

[Heart_SCCT @Heart_SCCT]

Exciting breakthroughs in cardiac CT technology will take center stage at #SCCT2025 in Montréal! Don't miss out on the latest advancements from SCCT industry partners

@circlecvi @Cleerlyhealth @ElucidBio @GEHealthCare @HeartFlow and @SiemensHealth

https://t.co/YQrrSeAxLG

[Dr. Kanwal M Farooqi @Kfarooqi]

🙌What a pleasure to give insight to an audience of enthusiastic CT technologists on publishing their work on #yesCCT. Happy to join on a panel of superstars 🌟
@ToddVillinesMD @Heart_SCCT @JWeirMcCall @OKhaliqueMD @AmroAlsaid @RonBlankstein @iamritu @Doc_Tiger @purviparwani

[Sagit Ben Zekry @SagitBen]

We are just about to begin! Congenital heart session #scct2025 #yesscct @Heart_SCCT

[Marcelo Godoy Zamorano🇨🇱 @marzagod]

Excited to be here. @SCCT #YesCCT #CardiacCT Tricuspid, pulmonic and LAAO workshop #SCCT2025

[Geetanjali Dang, MD MS FACC FASE @GeetanjaliDang]

Excited to attend #SCCT2025 in Toronto!! Lots of great sessions over the next 3 days!! @Heart_SCCT

[Annalisa Filtz @AnnalisaFiltz]

🤼 Amazing back and forth on #PlaqueMatters at #SCCT2025 !

🌟 Faculty @RonBlankstein @CsFuss @ToddVillinesMD @DrKelleyBranch @ghoshhajra @ednicolls

#YesSCCT @Heart_SCCT

@CardioMDPhD @MonteHeart

[Patrycja Galazka @PatrycjaGalazka]

“Business Aspects of Cardiac CT” - always a high impact session💥#SCCT2025 Topics included—
🧾 Reimbursement, advocacy &amp; proforma building
Congenital/structural heart disease in practice growth
👥 Staffing realities &amp; workflow
🏥 Hub-and-spoke models &amp; more. ⁦@Heart_SCCT⁩

[Renée Bullock-Palmer MD FACC FAHA FASNC FASE FSCCT @RBP0612]

Congratulations Dr. Nisha Hosadurg for the inaugural SCCT Chinnaiyan Catalyst Award. Looking forward to your research in Women's Cardiovascular Health #SCCT2025 @Heart_SCCT